Evidence map›Paper›PMID 42844497›Full record

ArticlePharmaceutical research2026

Polar vs Non-polar Excipients in BSA Aggregation.

Samuel Tien, Simone Nørgaard Krabbe, Annika Sollann Sørensen, Thomas Balle, Veysel Kayser

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samuel TienFaculty of Medicine and Health, The University of Sydney, Sydney School of Pharmacy, Sydney, NSW, 2006, Australia.ORCID http://orcid.org/0009-0004-6651-4415
Simone Nørgaard Krabbe *Faculty of Medicine and Health, The University of Sydney, Sydney School of Pharmacy, Sydney, NSW, 2006, Australia.
Annika Sollann Sørensen *Faculty of Medicine and Health, The University of Sydney, Sydney School of Pharmacy, Sydney, NSW, 2006, Australia.
Thomas BalleFaculty of Medicine and Health, The University of Sydney, Sydney School of Pharmacy, Sydney, NSW, 2006, Australia.
Veysel KayserFaculty of Medicine and Health, The University of Sydney, Sydney School of Pharmacy, Sydney, NSW, 2006, Australia. veysel.kayser@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn recent years, there has been a rapid expansion in the development of new protein therapeutics in the pharmaceutical industry. Problematically, proteins are conformationally and colloidally marginally stable, and thus it is necessary to formulate them using buffering and stabilizing agents.

methodsIn this study, we use experimental and computation techniques to evaluate the aggregation pathway, as well as the stabilizing properties of a range of excipients on a model protein; bovine serum albumin (BSA).

resultsOur results show that polar excipients (L-arginine and trimethylamine N-oxide) decrease BSA stability, whereas non-polar excipients (L-alanine and L-valine) enhances it. To elucidate molecular mechanisms behind these trends, we constructed a multi-step unfolding and aggregation model. Upon thermal stress, the protein system is driven to form a disrupted dimer/trimer species across a steep activation energy barrier. This acts as the primary kinetic bottleneck, as once these intermediate states form sufficiently, large aggregates in tetramers and pentamers form across a significantly lower energy barrier. High temperature molecular dynamics simulations reveal that the unfolding mode of the monomer is characterized by the detachment of its C-terminus domain, creating an extended, aggregation prone structure. Crucially, in the native structure, this flexible region contains the only prominent solvent exposed hydrophobic patch on an otherwise hydrophilic protein surface. Therefore, hydrophobic excipients are predicted to interface with this hotspot, stabilizing the folded structure and suppressing downstream aggregation formation.

conclusionsOverall, this work demonstrates that understanding the specific protein aggregation mechanisms is key for the rational selection of stabilizers.

Indexed as

excipient-protein interactionsformulationprotein aggregationsimulation

Identifiers

PMID42844497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.